This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeClinical InformationClinical InformationACIP RecommendationsWhat is TicoVacTM?What is TBE?Symptoms & Risk FactorsDemonstrated EffectivenessDosing & Administration SchedulePatient ResourcesOrder TicoVacTM
Prescribing Information Indication Patient Site
Order the TicoVacTM Vaccine Through Pfizer Prime

Example

Order vaccines directly through Pfizer Prime or call Pfizer Customer Service

Online ordering through Pfizer Prime allows you to submit a Pfizer order that will ship in 2-3 business days.

New Customers

To register for a Pfizer Prime account, please contact a customer service representative at
​​​​​​​1-800-666-7248.

Existing Customers

Already have a Pfizer Prime account?
Manage your account or place your order
 here.

Customer Service

Call 1-800-666-7248, Monday-Friday, 8 am–8 pm ET.


Reference:TicoVacTM (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.
WHAT IS TICOVACTM?

TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.1

Find out about TicoVacTM Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

May 2022 PP-TCV-USA-0102
You are now leaving Pfizer
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
​​​​​​​
PP-TCV-USA-0102
INDICATION AND USAGE TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.​​​​​​​
IMPORTANT SAFETY INFORMATION
  • TicoVacTM should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVacTM.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVacTM.
  • TicoVacTM may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVacTM.​​​​​​​
  • TicoVacTM contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).​​​​​​​
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVacTM were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVacTM were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events.
 
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.​​​​​​​
Please see full prescribing information for TicoVacTM here.
Indication TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.